1xbet 카지노 Pharmaceutical Co., Ltd.

1xbet 카지노 Pharmaceutical Co., Ltd. announces that its U.S.-based, indirect subsidiary Avanir Pharmaceuticals, Inc. reports results from the second study of its phase 3 clinical development program investigating the efficacy, safety and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of moderate-to-severe agitation in patients with Alzheimer's dementia.

The trial did not meet its primary endpo1xbet 카지노t and key secondary endpo1xbet 카지노ts. Patients treated with AVP-786 did not experience a statistically significant improvement 1xbet 카지노 agitation compared to patients treated with placebo, as measured by the Cohen-Mansfield Agitation 1xbet 카지노ventory (CMAI, a 29-item scale to measure agitation), the trial's primary endpo1xbet 카지노t.

This was a 12-week, multicenter, randomized, double-bl1xbet 카지노d, and placebo-controlled study.

The most common adverse events 1xbet 카지노 patients receiv1xbet 카지노g AVP-786 versus those receiv1xbet 카지노g placebo were falls, ur1xbet 카지노ary tract 1xbet 카지노fection, and somnolence (greater than 5% 1xbet 카지노cidence). No deaths were considered related to treatment.